RedHill Biopharma Ltd (RDHL)

[DorseyE]

RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
RedHill Biopharma Ltd.
Thu, November 12, 2020, 7:00 AM EST·23 min read
Q3/2020 net revenues of approximately $21 million, with gross profit of $10.6 million, or approximately 51%, up from $6.7 million and approximately 32% in Q2/2020
--
Strong growth for Talicia® with approximately 300% quarter-over-quarter prescription growth and rapid expansion of the prescriber base; Talicia achieved national coverage for 167 million lives since launch, with additional coverage expected
--
Two consecutive quarters of Movantik® prescription (TRx) growth, reversing the trend of prescription decline prior to RedHill acquisition
--
Opaganib’s COVID-19 global Phase 2/3 study advancing rapidly with nearly 50% of patients enrolled and U.S. Phase 2 study over 90% enrolled; Initiated manufacturing ramp-up in preparation for potential emergency use applications as early as Q1/2021
--
Commencing Phase 3 study with RHB-204 for first-line treatment of pulmonary NTM infections
--
Cash balance of approximately $51 million as of September 30, 2020
--
Management to host webcast today, at 8:30 a.m. EST